Wall Street analysts predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will announce $25.10 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings, with the lowest sales estimate coming in at $23.99 million and the highest estimate coming in at $27.30 million. BioDelivery Sciences International reported sales of $12.18 million during the same quarter last year, which would suggest a positive year over year growth rate of 106.1%. The company is expected to announce its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that BioDelivery Sciences International will report full-year sales of $101.51 million for the current financial year, with estimates ranging from $97.66 million to $107.25 million. For the next financial year, analysts anticipate that the firm will post sales of $145.36 million, with estimates ranging from $135.60 million to $153.34 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. The business had revenue of $19.77 million during the quarter, compared to analysts’ expectations of $19.60 million.
In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 484,752 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $4.22, for a total value of $2,045,653.44. Following the completion of the transaction, the director now owns 2,559,803 shares in the company, valued at approximately $10,802,368.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $5.00, for a total value of $10,000,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,339,037 shares of company stock valued at $21,313,438. 13.26% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. QCM Cayman Ltd. purchased a new position in BioDelivery Sciences International in the 1st quarter worth approximately $35,000. Advisor Group Inc. raised its position in shares of BioDelivery Sciences International by 56.3% in the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,943 shares in the last quarter. First Allied Advisory Services Inc. acquired a new position in shares of BioDelivery Sciences International in the 1st quarter valued at approximately $58,000. Means Investment CO. Inc. acquired a new position in shares of BioDelivery Sciences International in the 1st quarter valued at approximately $59,000. Finally, Close Asset Management Ltd raised its position in shares of BioDelivery Sciences International by 1,340.0% in the 1st quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 16,750 shares in the last quarter. Hedge funds and other institutional investors own 56.79% of the company’s stock.
Shares of NASDAQ:BDSI opened at $4.46 on Friday. The company has a debt-to-equity ratio of 1.90, a current ratio of 2.88 and a quick ratio of 2.57. BioDelivery Sciences International has a 1 year low of $2.35 and a 1 year high of $5.37. The stock has a market cap of $404.60 million, a PE ratio of -6.11 and a beta of 0.47.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Further Reading: Strangles
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.